Retatrutide and blood pressure — need advice

SleepDoc_PDX said:

CRP reduction on cardiovascular risk — this is the lab result that excites me most: Baseline hsCRP: 9.0 mg/L (high cardiovascular risk) Month 6 hsCRP:…

NNT calculation for cardiovascular risk clinical endpoints: NNT = 1/ARR (absolute risk reduction).

From SELECT trial: MACE at 39 months — 6.5% semaglutide vs 8.0% placebo. ARR = 1.5%. NNT = 67 over 3.3 years.

Compare to established therapies:

These NNTs are clinically meaningful and comparable to accepted cardiovascular interventions.

SleepDoc_PDX said:

CRP reduction on cardiovascular risk — this is the lab result that excites me most: Baseline hsCRP: 9.0 mg/L (high cardiovascular risk) Month 6 hsCRP:…

Vitamin deficiency cascade with cardiovascular risk: after 6+ months of reduced food intake, I developed a subtle but important pattern: low B12 → elevated homocysteine → increased cardiovascular risk marker.

The connection: B12 is a cofactor for homocysteine metabolism. Without adequate B12, homocysteine accumulates. This is ironic — taking a CV-protective medication while developing a CV risk factor from reduced nutrition.

Solution: comprehensive vitamin supplementation and regular lab monitoring. Don't let the medication's benefits be undermined by nutritional deficiencies.

SleepDoc_PDX said:

CRP reduction on cardiovascular risk — this is the lab result that excites me most: Baseline hsCRP: 9.0 mg/L (high cardiovascular risk) Month 6 hsCRP:…

Thank you — that is the clearest version of this I have read, and I have read a lot of them.

From the other side of the consultation, briefly.

I want to bring up the cardiovascular angle on cardiovascular risk.

The SELECT trial demonstrated a 20% reduction in MACE with semaglutide 2.4mg[1]. This is practice-changing because the CV benefit appears to be independent of the degree of weight loss — suggesting direct vascular and anti-inflammatory mechanisms.

For cardiovascular risk, this means we need to think beyond the primary outcome and consider the cardiovascular implications. The all-cause mortality reduction (HR 0.81) is the most clinically meaningful signal.

VanRx_Mike said:

I want to bring up the cardiovascular angle on cardiovascular risk.

Can confirm. Same sequence, different timescale.